DOW
loading...
NASDAQ
loading...
S&P
loading...




Action Alerts PLUS
RealMoney Silver
Market Movers
Stocks Under $10
Options Alerts
Breakout Stocks
View All


Now, enjoy the good life every day!

RSSRSS FEEDS
PODPODCASTS


RealMoney.com: Will Gabrielski
Print This Story

Board Members Bolt From Calpine

By William Gabrielski
RealMoney.com Contributor

9/21/2005 11:36 AM EDT
 
 Calpine (CPN:NYSE) BEARISH
Price: $2.79  |  52-Week Range: $1.32-$4.08
  • Two Calpine board members are leaving the company's board of directors.
  • Sources speculate that Jeffrey Garten wants to distance himself from Calpine's woes.
  • Garten worked in the Clinton administration and has long Wall Street bloodlines.
Position: None

Calpine (CPN - commentary - Cramer's Take) shares are under more pressure this morning, following Tuesday night's announcement that two board members -- Jeffrey Garten and John Wilson -- are leaving the company.



Garten is a well-respected businessman who served as undersecretary of commerce for former President Bill Clinton. Garten is the current dean of the Yale School of Management and has a strong Wall Street bloodline, including stints at The Blackstone Group and Shearson Lehman.

Wilson joined Calpine's board in 1997, shortly after the company's IPO, and plans to continue to serve as a faculty member of the University of California at Berkeley.

The company issued a press release saying the board had named William J. Keese, former chairman of the California Energy Commission, and Walter L. Revell, chairman and chief executive officer of Revell Investments International, to replace Garten and Wilson on the board.

The speculation among debt analysts and traders I spoke with is that the departure of Garten, which was effective as of Sept. 14, could be a sign that Calpine's walls are caving in and that Garten does not want to be associated with a company that could be on the verge of insolvency. This seems like a fair assessment based on my research, and I'd expect Calpine's current financial situation to gain more attention in light of this. I have contacted the company regarding these departures and am awaiting comment.

In other news, Calpine's planned $400 million preferred offering is not receiving a positive reaction on the Street. The deal size has been cut to $300 million, according to a report from DebtWire.com. And Calpine now plans to wait until February to buy back the $150 million preferred it issued in August, raising the question as to whether it will be able to get the $300 million deal done at all. But even if the deal does get done, the amount of time that has passed since the company announced its plans to issue these preferred securities leads me to believe the terms will not be favorable to Calpine.

By delaying the repayment of the $150 million, and cutting the deal size of the recently proposed preferred offering from $400 million to $300 million, Calpine's liquidity situation could be in an even worse position than I originally believed.

Finally, in response to Tuesday's column, Calpine sent me an email saying it could use the proceeds from its natural gas asset sale to acquire natural gas. The bondholders continue to disagree. But no matter who turns out to be right, the fact that Calpine's access to the funds it has with Bank of New York has been cut off is a negative for the company's ability to fund operations and secure natural gas.






 RELATED STORIES

Will Gabrielski
Calpine Runs Into a Cash Crunch
9/20/2005 4:00 PM EDT
The energy company's woes aren't over, and they may be getting worse.

Will Gabrielski
Calpine Still Looks Stuck in the Mud
9/13/2005 10:15 AM EDT
Its recent financing and partnership with Bear will help, but fail to resolve, the company's liquidity problems.

Will Gabrielski
The Confusion in Calpine's Upgrade
8/24/2005 3:01 PM EDT
An upgrade has shares moving higher today, but the analyst cites confusion around facts that seem clear.

Matthew Goldstein
Calpine Finds a Friend
9/8/2005 1:38 PM EDT
It teams with Bear Stearns in energy trading.

William Gabrielski
Calpine's Quick Fix a Bandage, Not a Cure
8/15/2005 10:46 AM EDT
Today's financing deal buys time, but doesn't solve the company's liquidity issues.



William Gabrielski is a research associate at TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Gabrielski welcomes your feedback; click here to send him an email.

Interested in more writings from William Gabrielski? Check out Stocks Under $10. For more information, click here.

Write us!
Order reprints of TSC articles. Top



Brokerage Partners


TheStreet Premium Services
Jim Cramer
Jim Cramer's Action Alerts PLUS
Now any level of investor can trade right alongside a Wall Street pro — and enjoy 24/7 access to his portfolio! Learn More
Doug Kass
RealMoney Silver
The genius of Doug Kass + 5 Premium Services = an unrivaled group of expert fundamental analysts, technical analysts, and Wall Street observers. Learn More
Don Dion
NEW! Don Dion's ETF Action
A concise two-step strategy for learning and trading in this increasingly lucrative area of investing. For all levels of investors! Learn More
David Peltier
Stocks Under $10
David Peltier is ready to help you find affordable stocks under $10. Because they're so inexpensive, the payout could be enormous! Learn More
Bryan Ashenberg
Breakout Stocks
Bryan Ashenberg combines sophisticated screening software with eagle-eye analysis to find small and mid-caps ready to break out! Learn More

Investor Relations | Privacy Policy | Terms of Use | Conflicts Policy | Corrections | Internet Index | Advertise | FAQ
Site Map | Who's Who | Reader Feedback | Employment | Contact Us
RSSSubscribe to our RSS Feed
© 1996- TheStreet.com, Inc. All rights reserved.
TheStreet.com's enterprise databases running Oracle are professionally monitored and managed by Pythian Remote DBA.